Brown Rudnick represented A2 Biotherapeutics in an agreement with Merck in which A2 will continue research and preclinical development of its undisclosed TmodTM cell therapy candidate (its third candidate therapy), with the parties to cofund A2's clinical development and allogeneic manufacturing activities through Phase 1. This notable deal enables A2 to build allogeneic capability. The Firm played a major role on the deal team as IP counsel to the company.

A2 is a biotechnology company using its next-generation cell therapy TmodTM platform to revolutionize the treatment of solid tumor cancers. The company engineers T cells that target the loss of genetic material in tumors, enabling the selective killing of tumor cells while leaving normal cells unharmed. For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. In this agreement with A2, Merck will assist with preclinical development and has the option to exclusively develop, manufacture and commercialize the candidate following Phase 1.

The Brown Rudnick deal team included Adam M. Schoen, Zachary D. Hyde, and Robert B. Ruh III.